Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1711 to 1725 of 7707 results

  1. Sleep disordered breathing

    Awaiting development [GID-QS10096] Expected publication date: TBC

    Quality standard
    Awaiting development

  2. Managing symptoms with an uncertain cause

    Awaiting development [GID-QS10103] Expected publication date: TBC

    Quality standard
    Awaiting development

  3. Secondary care management of malignant hypertension

    Awaiting development [GID-QS10107] Expected publication date: TBC

    Quality standard
    Awaiting development

  4. Prevention of dementia

    Awaiting development [GID-QS10109] Expected publication date: TBC

    Quality standard
    Awaiting development

  5. Gambling

    Awaiting development [GID-QS10099] Expected publication date: TBC

    Quality standard
    Awaiting development

  6. Vulnerable populations: strategies for tackling inequalities

    Awaiting development [GID-QS10124] Expected publication date: TBC

    Quality standard
    Awaiting development

  7. Gout

    Awaiting development [GID-QS10100] Expected publication date: TBC

    Quality standard
    Awaiting development

  8. Asunercept for treating glioblastoma [1301]

    In development [GID-TA10227] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]

    In development [GID-TA10225] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Glatiramer acetate depot for multiple sclerosis [TS ID 10620]

      Status ...

    Technology appraisal guidance
    Topic selection

  11. Emtricitabine/tenofovir alafenamide for human immunodeficiency virus type-1 infection [TS ID 10723]

      Status ...

    Technology appraisal guidance
    Topic selection

  12. Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TS ID 10085]

      Status ...

    Technology appraisal guidance
    Topic selection

  13. Dupilumab for children with severe atopic dermatitis [TS ID 10434]

      Status ...

    Technology appraisal guidance
    Topic selection

  14. Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765

    Awaiting development [GID-TA11050] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. REGN5458 for treating relapsed or refractory multiple myeloma TS ID 10443

    Awaiting development [GID-TA11052] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development